Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha) Clear all
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan, Pembrolizumab, Placebo
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
37
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 22, 2026, 1:12 AM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan, Everolimus
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • La Jolla, California • Santa Rosa, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 22, 2026, 1:12 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Belzutifan, Palbociclib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced May 22, 2026, 1:12 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer, Renal Cancer, Renal Cell Carcinoma, Renal Cell Cancer Metastatic, Renal Cell Carcinoma Recurrent, Renal Cell Cancer, Recurrent, Kidney
Interventions
Belzutifan, Cabozantinib
Drug
Lead sponsor
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced May 22, 2026, 1:12 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
33
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 22, 2026, 1:12 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced May 22, 2026, 1:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Healthy Participants
Interventions
Casdatifan, Itraconazole, Phenytoin
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced May 22, 2026, 1:12 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
HIF-2alpha Inhibitor PT2385, Pharmacological Study, Laboratory Biomarker Analysis, Pharmacogenomic Study
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced May 22, 2026, 1:12 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
18
States / cities
Washington D.C., District of Columbia • Miami, Florida • Louisville, Kentucky + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced May 22, 2026, 1:12 AM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell
Interventions
Oral NKT2152
Drug
Lead sponsor
NiKang Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced May 22, 2026, 1:12 AM EDT